AGIO Agios Pharmaceuticals, Inc. Stock Quote

AGIO [NASD]

Index	-	P/E	-	EPS (ttm)	-5.50	Insider Own	0.30%	Shs Outstand	61.07M	Perf Week	0.81%
Market Cap	2.72B	Forward P/E	-	EPS next Y	-7.21	Insider Trans	-36.15%	Shs Float	55.60M	Perf Month	7.90%
Income	-370.30M	PEG	-	EPS next Q	-1.59	Inst Own	-	Short Float	10.14%	Perf Quarter	-16.22%
Sales	78.80M	P/S	34.54	EPS this Y	30.80%	Inst Trans	0.19%	Short Ratio	7.68	Perf Half Y	-4.27%
Book/sh	28.20	P/B	1.69	EPS next Y	-127.70%	ROA	103.90%	Target Price	62.43	Perf Year	40.30%
Cash/sh	29.21	P/C	1.63	EPS next 5Y	40.00%	ROE	130.00%	52W Range	32.47 - 62.15	Perf YTD	9.67%
Dividend	-	P/FCF	-	EPS past 5Y	-8.60%	ROI	-	52W High	-23.55%	Beta	1.62
Dividend %	-	Quick Ratio	-	Sales past 5Y	28.00%	Gross Margin	98.00%	52W Low	46.35%	ATR	1.35
Employees	562	Current Ratio	28.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.39	Volatility	2.63% 2.79%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-14.70%	Profit Margin	-	Rel Volume	0.37	Prev Close	47.75
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 29 BMO	Payout	0.00%	Avg Volume	733.59K	Price	47.52
Recom	2.50	SMA20	3.85%	SMA50	1.25%	SMA200	-5.51%	Volume	271,387	Change	-0.48%

Jul-30-21

Downgrade

Goldman

Neutral → Sell

$58 → $39

Jul-01-21

Initiated

Raymond James

Mkt Perform

Jun-10-21

Initiated

H.C. Wainwright

Buy

$88

Mar-01-21

Upgrade

SVB Leerink

Mkt Perform → Outperform

$50

Mar-01-21

Downgrade

JP Morgan

Overweight → Neutral

$64 → $54

Feb-26-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Oct-22-20

Upgrade

Barclays

Equal Weight → Overweight

$46

Mar-04-20

Initiated

Barclays

Equal Weight

$50

Nov-26-19

Initiated

Cantor Fitzgerald

Overweight

$64

Sep-23-19

Upgrade

Guggenheim

Neutral → Buy

$55

May-23-19

Resumed

Goldman

Neutral

$55

Feb-15-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

$80

Sep-25-18

Initiated

Leerink Partners

Mkt Perform

May-23-18

Initiated

Citigroup

Buy

$117

Apr-11-18

Reiterated

Credit Suisse

Outperform

$80 → $95

Feb-15-18

Reiterated

SunTrust

Buy

$80 → $101

Feb-15-18

Reiterated

Needham

Buy

$72 → $86

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$78

Aug-10-17

Reiterated

Needham

Buy

$54 → $72

Aug-08-17

Reiterated

SunTrust

Buy

$68 → $80

Sep-20-21 02:57PM	Top Biotech Stocks for Q4 2021 Investopedia
Aug-30-21 07:00AM	Agios To Present at September Investor Conferences GlobeNewswire
Aug-24-21 09:00AM	Ex-Peloton Therapeutics CEO launches biotech startup with $60M American City Business Journals
Aug-18-21 10:05AM	Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review Zacks -5.38%
07:37AM	The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga
Aug-17-21 04:01PM	Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jul-31-21 03:13AM	Would Shareholders Who Purchased Agios Pharmaceuticals' (NASDAQ:AGIO) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Jul-30-21 12:10PM	Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress Zacks
Jul-29-21 05:00PM	Agios Pharmaceuticals, inc (AGIO) Q2 2021 Earnings Call Transcript Motley Fool
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	Agios Reports Business Highlights and Second Quarter 2021 Financial Results GlobeNewswire
Jul-22-21 03:03PM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks -7.77%
Jul-19-21 12:16PM	Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Jul-15-21 07:00AM	Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021 GlobeNewswire
Jun-29-21 11:15AM	Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug Zacks
Jun-28-21 07:00AM	Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jun-25-21 03:44PM	Top Stocks for July 2021 Investopedia
Jun-23-21 01:11PM	Top Healthcare Stocks for July 2021 Investopedia
Jun-22-21 11:45AM	Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat Zacks -7.23%
07:00AM	Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency GlobeNewswire
Jun-21-21 11:07AM	Agios Pharma Files US Application For Mitapivat In PK Deficiency Benzinga
07:00AM	Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency GlobeNewswire
Jun-18-21 09:58AM	Obamacare survives: what it means for the future of health care Yahoo Finance Video
Jun-11-21 03:00AM	Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent - and -Thalassemia at the European Hematology Association Virtual Congress GlobeNewswire
03:00AM	Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress GlobeNewswire
May-12-21 10:00AM	Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress GlobeNewswire
09:32AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Insider Monkey
May-02-21 03:08AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Is About To Turn The Corner Simply Wall St.
Apr-30-21 08:46AM	Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress Zacks
Apr-29-21 06:30PM	Agios Pharmaceuticals Inc (AGIO) Q1 2021 Earnings Call Transcript Motley Fool
09:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Agios Reports Business Highlights and First Quarter 2021 Financial Results GlobeNewswire
05:45AM	Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Apr-22-21 12:33PM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-20-21 11:56AM	Is AGIO Stock A Buy or Sell? Insider Monkey
Apr-15-21 07:00AM	Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021 GlobeNewswire
Apr-01-21 07:00AM	Agios Announces Closing of Oncology Business Sale to Servier GlobeNewswire
Mar-27-21 11:31AM	Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report? Zacks
Mar-25-21 04:01PM	Agios Shareholders Approve Sale of Oncology Business to Servier GlobeNewswire
Mar-18-21 07:00AM	Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease GlobeNewswire -5.88%
Mar-01-21 07:00AM	Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma GlobeNewswire
Feb-27-21 01:04AM	Time To Worry? Analysts Just Downgraded Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Outlook Simply Wall St.
Feb-26-21 10:04AM	Benzinga's Top Ratings Upgrades, Downgrades For February 26, 2021 Benzinga -5.67%
09:21AM	Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates Zacks
07:00AM	Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias GlobeNewswire
Feb-25-21 07:00PM	Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript Motley Fool
07:00AM	Agios Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
06:15AM	Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 07:00AM	Agios to Present at March Investor Conferences GlobeNewswire
Feb-11-21 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021 GlobeNewswire
Feb-04-21 11:54PM	Introducing Agios Pharmaceuticals (NASDAQ:AGIO), A Stock That Climbed 41% In The Last Five Years Simply Wall St.
Jan-27-21 07:35AM	The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga
Jan-26-21 04:01PM	Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused GlobeNewswire
Jan-17-21 10:00AM	Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma GlobeNewswire
Jan-11-21 07:00AM	Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation GlobeNewswire
Jan-05-21 07:00AM	Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 GlobeNewswire
Dec-23-20 08:30AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? Zacks
Dec-22-20 10:22AM	Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up Zacks
07:39AM	4 Reasons Agios' Oncology Deal Should Please Investors Motley Fool
Dec-21-20 04:25PM	This Biotech Stock Just Made A $2 Billion Sale And Shares Rocketed Investor's Business Daily +28.33%
01:46PM	Agios Stock Is Soaring Because of a Major Sale Barrons.com
11:44AM	Why Agios Pharmaceuticals Stock Is Soaring Today Motley Fool
10:10AM	Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up Panoptes Benzinga
09:30AM	Agios Soars on Plan to Sell Cancer Drugs, Return $1.2B to Holders TheStreet.com
07:39AM	Agio's shares jump 20% after announcing plans to sell cancer portfolio MarketWatch
07:00AM	Agios to sell cancer business to Servier for potentially $2 bln Reuters
07:00AM	Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties GlobeNewswire
Dec-20-20 05:16PM	Is AGIO A Good Stock To Buy Now? Insider Monkey
Dec-07-20 04:30PM	Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease GlobeNewswire
Dec-05-20 11:31AM	Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-20 08:00AM	New Results on Blood Disorder Treatments Are Coming. Watch These Stocks. Barrons.com
Dec-02-20 10:55AM	Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal Zacks
Dec-01-20 07:00AM	Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused GlobeNewswire
Nov-30-20 07:00AM	Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias GlobeNewswire
Nov-25-20 07:00AM	Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 GlobeNewswire
Nov-20-20 10:14AM	Unusual Options Activity Insight: Agios Pharmaceuticals Benzinga
Nov-13-20 10:57AM	Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD Zacks
Nov-12-20 04:30PM	Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease GlobeNewswire
Nov-07-20 07:16AM	Analyst Estimates: Here's What Brokers Think Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Third-Quarter Report Simply Wall St.
Nov-06-20 11:20AM	Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss Zacks -6.77%
Nov-05-20 09:00PM	Agios Pharmaceuticals Inc (AGIO) Q3 2020 Earnings Call Transcript Motley Fool
08:23AM	Agios Pharmaceuticals: Q3 Earnings Insights Benzinga
07:00AM	Agios Reports Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
06:15AM	Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 11:46AM	Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting GlobeNewswire
Oct-30-20 06:29AM	We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely Simply Wall St.
Oct-29-20 04:01PM	Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020 GlobeNewswire
12:35PM	Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-22-20 12:34PM	Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +9.83%
07:00AM	Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 GlobeNewswire
Oct-19-20 12:06PM	Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU Zacks
Oct-16-20 04:01PM	Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia GlobeNewswire
Oct-05-20 12:00PM	All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy Zacks +8.77%
Sep-21-20 07:00AM	Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients GlobeNewswire -5.15%
Sep-16-20 05:10PM	Hedge Funds Have Never Been This Bullish On Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Sep-08-20 04:01PM	Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs GlobeNewswire
Sep-05-20 07:27AM	2 Mid-Cap Healthcare Stocks to Buy Now Motley Fool
Aug-31-20 06:35AM	Who Has Been Buying Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? Simply Wall St.
Aug-29-20 11:31AM	Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound? Zacks
Aug-27-20 07:00AM	Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 GlobeNewswire

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alenson Carman	Principal Accounting Officer	Jun 21	Option Exercise	51.51	1,777	91,533	1,777	Jun 23 05:28 PM
Alenson Carman	Principal Accounting Officer	Jun 21	Sale	61.61	1,777	109,481	0	Jun 23 05:28 PM
Bowden Christopher	Chief Medical Officer	Jun 18	Option Exercise	49.99	48,493	2,423,991	63,980	Jun 22 04:44 PM
Bowden Christopher	Chief Medical Officer	Jun 18	Sale	60.11	48,493	2,914,851	15,487	Jun 22 04:44 PM
Bowden Christopher	Chief Medical Officer	Jun 17	Option Exercise	39.76	2,502	99,480	17,989	Jun 21 04:18 PM
Bowden Christopher	Chief Medical Officer	Jun 17	Sale	60.02	2,502	150,170	15,487	Jun 21 04:18 PM
Bowden Christopher	Chief Medical Officer	Jun 10	Option Exercise	39.76	20,853	829,115	36,340	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 10	Sale	60.06	20,853	1,252,437	15,487	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 09	Option Exercise	39.76	7,149	284,244	22,636	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 09	Sale	60.16	7,149	430,117	15,487	Jun 11 05:00 PM
Bowden Christopher	Chief Medical Officer	Jun 08	Option Exercise	39.76	6,675	265,398	22,162	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 08	Sale	60.07	6,675	400,939	15,487	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 07	Option Exercise	39.76	4,268	169,696	19,755	Jun 09 04:06 PM
Bowden Christopher	Chief Medical Officer	Jun 07	Sale	60.04	4,268	256,232	15,487	Jun 09 04:06 PM
MARAGANORE JOHN	Director	May 28	Option Exercise	0.00	1,686	0	28,443	Jun 02 04:09 PM
CLARK IAN T	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:09 PM
Schenkein David P	Director	May 28	Option Exercise	0.00	1,686	0	114,277	Jun 02 04:07 PM
Clancy Paul J	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:07 PM
Foster-Cheek Kaye I	Director	May 28	Option Exercise	0.00	1,686	0	7,164	Jun 02 04:08 PM
Scadden David	Director	May 28	Option Exercise	0.00	1,686	0	5,535	Jun 02 04:07 PM
Ho Maykin	Director	May 28	Option Exercise	0.00	1,686	0	4,964	Jun 02 04:06 PM
Miles Darrin	Chief Commercial Officer	May 14	Sale	55.41	3,462	191,829	7,209	May 18 04:11 PM
Alenson Carman	Principal Accounting Officer	Apr 16	Sale	55.89	1,118	62,485	0	Apr 20 04:10 PM
Alenson Carman	Principal Accounting Officer	Apr 15	Sale	54.00	991	53,514	1,118	Apr 16 04:33 PM
Miles Darrin	Chief Commercial Officer	Mar 05	Sale	48.58	500	24,290	10,671	Mar 16 04:14 PM
Miles Darrin	Chief Commercial Officer	Mar 01	Sale	47.99	2,200	105,578	11,171	Mar 16 04:14 PM
Miles Darrin	Chief Commercial Officer	Feb 22	Option Exercise	0.00	725	0	13,272	Feb 24 04:14 PM
Schenkein David P	Director	Feb 22	Option Exercise	0.00	2,774	0	113,412	Feb 24 04:12 PM
Bowden Christopher	Chief Medical Officer	Feb 22	Option Exercise	0.00	3,334	0	16,396	Feb 24 04:11 PM
Alenson Carman	Principal Accounting Officer	Feb 22	Option Exercise	0.00	692	0	1,994	Feb 24 04:12 PM
Schenkein David P	Director	Feb 16	Option Exercise	0.00	8,125	0	113,178	Feb 17 04:12 PM
Alenson Carman	Principal Accounting Officer	Feb 16	Option Exercise	0.00	790	0	1,863	Feb 17 04:13 PM
Miles Darrin	Chief Commercial Officer	Feb 16	Option Exercise	0.00	922	0	15,463	Feb 17 04:14 PM
Bowden Christopher	Chief Medical Officer	Feb 16	Option Exercise	0.00	2,750	0	15,131	Feb 17 04:14 PM
Bowden Christopher	Chief Medical Officer	Feb 14	Option Exercise	0.00	4,000	0	12,381	Feb 17 04:14 PM
Miles Darrin	Chief Commercial Officer	Feb 14	Option Exercise	0.00	8,666	0	14,541	Feb 17 04:14 PM
Alenson Carman	Principal Accounting Officer	Feb 14	Option Exercise	0.00	889	0	1,073	Feb 17 04:13 PM
FOUSE JACQUALYN A	Chief Executive Officer	Feb 14	Option Exercise	0.00	11,333	0	61,761	Feb 17 04:13 PM
Car Bruce	Chief Scientific Officer	Jan 06	Option Exercise	0.00	3,437	0	8,284	Apr 15 04:46 PM
Biller Jonathan	Chief Financial Officer	Dec 03	Option Exercise	0.00	5,753	0	11,747	Dec 07 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience